Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GIMEMA ALL 0394

 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Antineoplastic Combined Chemotherapy ProtocolsCytarabineEtoposideIdarubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two…
Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2019
2019
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion‐dependent patients with myelodysplastic syndromes
Most patients affected by Myelodysplastic syndromes (MDS) develop transfusion dependence, which can be correlated with poorer… Expand
2018
2018
Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3…
Introduction: The phase 3 GIMEMA-MMY-3006 trial comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide… Expand
2015
2015
Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients
Introduction: Several studies demonstrated that continuous therapy (CT) prolonged progression-free survival (PFS); conflicting… Expand
2015
2015
Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple…
Introduction The introduction of novel agents in the treatment of Multiple Myeloma (MM) led to a significant improvement in the… Expand
2014
2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2014
2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
2013
2013
Absolute monocyte count at diagnosis and survival in mantle cell lymphoma
Chaperot, L., Bendriss, N., Manches, O., Gressin, R., Maynadie, M., Trimoreau, F., Orfeuvre, H., Corront, B., Feuillard, J… Expand
Highly Cited
2005
Highly Cited
2005
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.
The role of all-trans retinoic acid (ATRA) in pediatric acute promyelocytic leukemia (APL) is the topic of several ongoing… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2004
2004
Intensification of Post-Remissional Treatment in Adult Acute Lymphoblastic Leukemia (ALL) with t(4;11) or t(1;19): Results of the GIMEMA LAL 2000 Study.
In the GIMEMA LAL 0496 trial, which has been conducted in Italy between 1996 and 2000, patients with adult ALL received an… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE